Theratechnologies(US:THTX) Newsfilter·2025-04-09 11:30Core Insights - Theratechnologies reported a total revenue of $19 million for Q1 2025, reflecting a year-over-year growth of 17% [2][15][30] - The company achieved a net profit of $117,000, a significant improvement from a net loss of $4.48 million in Q1 2024 [30][34] - EGRIFTA SV® net sales increased by 44.8% to $13.88 million, while Trogarzo® sales decreased by 22.4% to $5.17 million [2][18] Financial Performance - Total revenue for Q1 2025 was $19,047,000 compared to $16,247,000 in Q1 2024, marking a 17.2% increase [15] - EGRIFTA SV® sales reached $13,880,000, up from $9,586,000 in the previous year, driven by higher unit sales and pricing [16] - Trogarzo® sales fell to $5,167,000 from $6,661,000, primarily due to lower unit sales [18] Recent Developments - The FDA approved EGRIFTA WR™ on March 25, 2025, which is expected to enhance the company's product offerings for treating excess visceral abdominal fat in adults with HIV [3][37] - The company resumed distribution of EGRIFTA SV® on February 14, 2025, following a temporary supply disruption due to a manufacturing shutdown [9][36] - The approval of the Prior Approval Supplement (PAS) for EGRIFTA SV® on April 7, 2025, allows for regular distribution without further FDA authorization [10][37] Research and Development - R&D expenses decreased by 21.2% to $2,969,000 in Q1 2025, attributed to lower spending on life-cycle management and oncology programs [22] - The company presented data at CROI highlighting the limitations of BMI in assessing cardiovascular risk in people with HIV [11] Guidance and Outlook - The company estimates FY2025 revenue to be between $80 million and $83 million, considering the impact of the supply disruption and the new product launch [13] - Adjusted EBITDA for Q1 2025 was $2,321,000, a significant improvement from a loss of $247,000 in the same period last year [28]